Novo Nordisk Faces Legal Probe As Trial Setback Reshapes Risk Expectations [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Pomerantz LLP has launched an investigation into Novo Nordisk (NYSE:NVO) for potential securities fraud linked to its CagriSema Phase 3 trial results. The probe follows disappointing CagriSema data and a recent FDA warning letter regarding adverse event reporting practices. The new legal scrutiny adds to existing regulatory questions and introduces an additional source of risk for current and prospective shareholders. Novo Nordisk, trading on the NYSE under ticker NVO, last closed at $37.96 after a period of sharp share price pressure. The stock has declined 23.4% over the past 30 days and 27.5% year to date, with a 49.8% drop over the past year and a 43.5% decline over three years, partly reflecting rising concern around its clinical and regulatory setbacks. These moves frame the Pomerantz investigation as another factor investors now have to weigh in addition t
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- When generic versions of weight-loss drugs arrive, public plans should cover them, experts say [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- FDA: Novo Nordisk failed to report deaths of weight-loss drug patients [USA TODAY]USA TODAY
- Novo Nordisk Patent Loss In India Tests GLP 1 Valuation Story [Yahoo! Finance]Yahoo! Finance
- Eli Lilly Just Opened the Door to Even Greater GLP-1 Growth [Yahoo! Finance]Yahoo! Finance
- Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/9/26 - Form 6-K
- 3/2/26 - Form 6-K
- 3/2/26 - Form 6-K
- NVO's page on the SEC website